382 studies found for:    dialysis [CONDITION] OR dialysis [TREATMENT] | Open Studies
Show Display Options
Download search resultsDownload the search results for:
dialysis [CONDITION] OR dialysis [TREATMENT] | Open Studies (382 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Not yet recruiting Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis
Conditions: Functionally Anuric;   Hemodialysis/Peritoneal Dialysis
Intervention: Other: Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis
2 Unknown  Decreasing Dialysis Cardiovascular Risk: Daily Versus Longer Treatments
Condition: Cardiovascular Disease
Intervention: Procedure: dialysis
3 Recruiting The Effect of Intra-abdominal t-PA and and DNase on Peritonitis in Peritoneal Dialysis Patients
Conditions: Peritoneal Dialysis;   Peritoneal Dialysis, Continuous Ambulatory
Interventions: Drug: Tissue Plasminogen Activator (tPA);   Drug: recombinant deoxyribonuclease (DNase)
4 Not yet recruiting Virtual Ward for Home Dialysis
Conditions: End Stage Renal Disease;   Kidney Failure;   Home Dialysis
Interventions: Other: Telephone follow-up;   Other: Sympton Assessment
5 Recruiting Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
Conditions: End-stage Renal Disease (ESRD);   Kidney Disease
Interventions: Other: DIANEAL;   Other: EXTRANEAL
6 Recruiting An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Conditions: Healthy Subjects;   Cytomegalovirus Infection;   Dialysis
Interventions: Drug: ASP0113;   Drug: Placebo
7 Unknown  Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients
Conditions: End-Stage Kidney Disease;   Peritoneal Dialysis
Intervention: Drug: N-acetylcysteine
8 Recruiting Peritoneal Dialysis Versus Haemodialysis
Condition: Hemodialysis
Interventions: Procedure: Peritoneal dialysis;   Procedure: Haemodialysis
9 Unknown  The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis
Conditions: Peritoneal Dialysis;   Hemodialysis
Intervention:
10 Recruiting Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects
Condition: CKD Anemia in Stable Dialysis Patients
Interventions: Drug: Epoetin Alfa;   Drug: FG-4592
11 Not yet recruiting Improving Outcomes in Peritoneal Dialysis
Conditions: Chronic Kidney Disease;   Peritoneal Dialysis Access
Intervention:
12 Unknown  Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients
Condition: End-Stage Renal Disease
Interventions: Drug: 6 L dialysate;   Drug: 8 L dialysate
13 Recruiting A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration
Condition: End Stage Renal Disease
Intervention: Other: Dialysis session of at least 4.25 hours
14 Unknown  Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis
Conditions: End Stage Renal Disease;   Peritoneal Dialysis
Intervention:
15 Recruiting The Role of Peritoneal Dialysis in Patients With Refractory Heart Failure and Chronic Kidney Disease
Conditions: Refractory Heart Failure;   Chronic Kidney Disease
Intervention: Drug: Peritoneal dialysis (PD)
16 Not yet recruiting Drug Eluting Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis Fistulas
Condition: Dialysis Access Dysfunction
Interventions: Drug: paclitaxel (Cardionovum Legflow drug eluting balloon);   Device: Balloon angioplasty (Bard Dorado)
17 Recruiting The Effects Nutrition Status and Body Composition On Peritoneal Dialysis Outcome
Conditions: Peritoneal Dialysis;   Wasting and Malnutrition
Intervention:
18 Unknown  Bioimpedance as a Tool for Fluid Management in Peritoneal Dialysis (PD) Patients
Conditions: Fluid Status;   Peritoneal Dialysis
Intervention:
19 Unknown  Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?
Condition: Peritoneal Dialysis
Intervention: Drug: alendronate (Fosamax)
20 Unknown  Effect of N-Acetylcysteine on Peritoneal Membrane Function in Chronic Peritoneal Dialysis Patients
Conditions: ESRD;   Peritoneal Dialysis
Intervention: Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years